Progress in optimizing the immunization schedule of recombinant human papillomavirus vaccines
10.3760/cma.j.cn112309-20210223-00061
- VernacularTitle:重组人乳头瘤病毒疫苗免疫程序优化的研究进展
- Author:
Guohua ZHONG
1
;
Shudan SHEN
;
Shoujie HUANG
;
Ting WU
Author Information
1. 厦门大学公共卫生学院，国家传染病诊断试剂与疫苗工程技术研究中心，分子疫苗学和分子诊断学国家重点实验室 361102
- Keywords:
Human papillomavirus;
Vaccine;
Immunization schedule;
Immunogenicity;
Efficacy
- From:
Chinese Journal of Microbiology and Immunology
2021;41(11):893-900
- CountryChina
- Language:Chinese
-
Abstract:
Human papillomavirus (HPV) is closely associated with cervical cancer and other anogenital cancers or diseases, and HPV vaccination is an important measure of primary prevention. Currently, there are four licensed HPV vaccines. Clinical trials and real-world studies have confirmed the efficacy and effectiveness of the routine three-dose immunization schedule. Expanding HPV vaccination coverage can accelerate the process of cervical cancer elimination, so optimizing the immunization schedule, including extending dosing intervals and decreasing vaccination doses, is one of the key considerations for future application of HPV vaccines. This review summarized the progress related to the immunogenicity and efficacy of HPV vaccination with fewer doses and non-standard three-dose schedule.
